Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-299
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LM-299 is an investigational bispecific antibody designed to target both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). By simultaneously inhibiting the PD-1/PD-L1 immune checkpoint pathway and the VEGF/VEGFR angiogenesis pathway, LM-299 aims to enhance anti-tumor immunity while suppressing tumor blood vessel formation. The molecule features a differentiated design with an anti-VEGF antibody linked to two C-terminal single domain anti-PD-1 antibodies. Developed initially by LaNova Medicines Ltd., Merck has acquired exclusive global rights for its development, manufacturing, and commercialization. As of late 2024, LM-299 is in Phase 2 clinical trials for advanced solid tumors in China, with plans for further trials in the United States[1][2][3][5][6].
- Other names
- LM-299LM299LM 299
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on LM-299.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM-299.